Udenafil (JURVIGO®)
Improvement of exercise capacity in adolescents with Fontan physiology
Key Facts
About Mezzion Pharmaceuticals
Mezzion Pharmaceuticals is a rare disease company singularly focused on addressing the unmet medical needs of the Fontan patient community. Its primary asset is udenafil (JURVIGO®), a PDE5 inhibitor currently in a confirmatory Phase 3 trial (FUEL-2) for adolescents aged 12-18 with Fontan circulation, following a prior positive Phase 3 study (FUEL). The company is led by a founder-CEO with a financial background and a President/COO with deep expertise in PDE5 inhibitor development, positioning it to potentially bring the first FDA-approved therapy to this specific orphan indication. Mezzion operates as a private, clinical-stage biotech with a clear, patient-centric mission.
View full company profile